Conmed Shareholders Approve Key Proposals at Annual Meeting

The latest update is out from Conmed ( (CNMD) ).

At the Company’s Annual Meeting of Stockholders on May 20, 2025, CONMED Corporation’s shareholders voted on four key proposals. Eight directors were elected, executive compensation was approved, the 2025 Long-Term Incentive Plan was passed, and PricewaterhouseCoopers LLP was ratified as the independent auditor for fiscal 2025. Additionally, the Board declared a quarterly cash dividend of $0.20 per share, payable on July 3, 2025, to shareholders of record as of June 13, 2025.

The most recent analyst rating on (CNMD) stock is a Buy with a $106.00 price target. To see the full list of analyst forecasts on Conmed stock, see the CNMD Stock Forecast page.

Spark’s Take on CNMD Stock

According to Spark, TipRanks’ AI Analyst, CNMD is a Outperform.

Conmed’s overall stock score reflects a strong financial performance supported by solid cash flow and revenue growth, offset by high leverage. The stock appears undervalued based on its P/E ratio, adding to its attractiveness. Positive earnings guidance and strategic corporate events further bolster the stock’s outlook, despite challenges like supply chain issues and currency impacts.

To see Spark’s full report on CNMD stock, click here.

More about Conmed

Average Trading Volume: 514,546

Technical Sentiment Signal: Strong Sell

Current Market Cap: $1.86B

Learn more about CNMD stock on TipRanks’ Stock Analysis page.